Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2010

Open Access 01-12-2010 | Commentary

Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist

Authors: Maria Eliane C Magalhães, Breno A Cavalcanti, Saulo Cavalcanti

Published in: Diabetology & Metabolic Syndrome | Issue 1/2010

Login to get access

Abstract

The prevalence of pre-diabetes is increasing worldwide and may start 7 to 10 years before the clinical diagnosis of diabetes. In this stage the presence and accumulation of risk factors is common and already implies an increase in cardiovascular risk. Likewise, the onset of cardiovascular diseases (CVD), mainly coronary artery disease (CAD), peripheral vascular disease and cerebrovascular disease can also take place, all of which account for high rates of morbidity and mortality worldwide. Considering pre-diabetes as a clinical entity, non-pharmacological and pharmacological treatments are indicated with drugs which have shown clinical benefits related to reduction in morbidity and mortality. However, there is still need for new long-term studies to assess the real benefits of several new therapeutical approaches, as well as its cost-effectiveness.
Literature
1.
go back to reference DeFronzo RA: From the triumvirate to the ominous octet: a new paradigma for the treatment of type 2 diabetes. Diabetes. 2009, 58: 773-795. 10.2337/db09-9028.PubMedCentralCrossRefPubMed DeFronzo RA: From the triumvirate to the ominous octet: a new paradigma for the treatment of type 2 diabetes. Diabetes. 2009, 58: 773-795. 10.2337/db09-9028.PubMedCentralCrossRefPubMed
2.
go back to reference Buttler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: B cell deficit and increase beta cell apoptosis in humans with type 2 diabetes. Diabetes. 2003, 52: 102-110. 10.2337/diabetes.52.1.102.CrossRef Buttler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: B cell deficit and increase beta cell apoptosis in humans with type 2 diabetes. Diabetes. 2003, 52: 102-110. 10.2337/diabetes.52.1.102.CrossRef
3.
go back to reference Escandon JC, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Reviews. 2001, 22: 36-52. 10.1210/er.22.1.36.CrossRef Escandon JC, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Reviews. 2001, 22: 36-52. 10.1210/er.22.1.36.CrossRef
4.
go back to reference National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979, 28: 1039-1057.CrossRef National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979, 28: 1039-1057.CrossRef
5.
go back to reference American Diabetes Association: Clinical practice recommendations Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008, 28 (suppl 1): S55-S60. 10.2337/dc08-S055.CrossRef American Diabetes Association: Clinical practice recommendations Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008, 28 (suppl 1): S55-S60. 10.2337/dc08-S055.CrossRef
6.
go back to reference Wild S, Roglic A, Sicree R, King H: Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-53. 10.2337/diacare.27.5.1047.CrossRefPubMed Wild S, Roglic A, Sicree R, King H: Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-53. 10.2337/diacare.27.5.1047.CrossRefPubMed
7.
go back to reference Stern SE, Williams K, Ferranini E, DeFronzo RA, Bogardus C, Stern MP: Identification of individuals with insulin resistance using routine measurements. Diabetes. 2005, 54: 333-9. 10.2337/diabetes.54.2.333.CrossRefPubMed Stern SE, Williams K, Ferranini E, DeFronzo RA, Bogardus C, Stern MP: Identification of individuals with insulin resistance using routine measurements. Diabetes. 2005, 54: 333-9. 10.2337/diabetes.54.2.333.CrossRefPubMed
8.
go back to reference Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002, 346: 393-403. 10.1056/NEJMoa012512.PubMedCentralCrossRef Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002, 346: 393-403. 10.1056/NEJMoa012512.PubMedCentralCrossRef
9.
go back to reference UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853. 10.1016/S0140-6736(98)07019-6.CrossRef UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998, 352: 837-853. 10.1016/S0140-6736(98)07019-6.CrossRef
10.
go back to reference The DECODE Study Group: the Current Definition for Diabetes Relevant to Mortality Risk From All Causes and Cardiovascular and Noncardiovascular Diseases?. Diabetes Care. 2003, 26: 688-699. 10.2337/diacare.26.3.688.CrossRef The DECODE Study Group: the Current Definition for Diabetes Relevant to Mortality Risk From All Causes and Cardiovascular and Noncardiovascular Diseases?. Diabetes Care. 2003, 26: 688-699. 10.2337/diacare.26.3.688.CrossRef
11.
go back to reference Tratamento e acompanhamento do Diabetes Mellitus: Em Classificação Etiológica do Diabetes Mellitus. Diretrizes da Sociedade Brasileira de Diabetes. 2007, 11-13. Tratamento e acompanhamento do Diabetes Mellitus: Em Classificação Etiológica do Diabetes Mellitus. Diretrizes da Sociedade Brasileira de Diabetes. 2007, 11-13.
12.
go back to reference Sociedade Brasileira de Cardiologia: V Diretrizes Brasileiras de Hipertensão Arterial. Arq Bras Cadiol. 2007, 89: 1-79. Sociedade Brasileira de Cardiologia: V Diretrizes Brasileiras de Hipertensão Arterial. Arq Bras Cadiol. 2007, 89: 1-79.
13.
go back to reference Mancia G, De Backer G, Dominiczak A: Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007, 25: 1105-87. 10.1097/HJH.0b013e3281fc975a.CrossRefPubMed Mancia G, De Backer G, Dominiczak A: Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007, 25: 1105-87. 10.1097/HJH.0b013e3281fc975a.CrossRefPubMed
14.
go back to reference Abdul-Ghani MA, Tripathy D, DeFronzo RA: Contribution of B-cell Dysfunction and insulin resistance to the Pathogenesis of Impaire Glucose Tolerance and impaired fasting glucose. Diabetes Care. 2006, 29: 1130-1139. 10.2337/dc05-2179.CrossRefPubMed Abdul-Ghani MA, Tripathy D, DeFronzo RA: Contribution of B-cell Dysfunction and insulin resistance to the Pathogenesis of Impaire Glucose Tolerance and impaired fasting glucose. Diabetes Care. 2006, 29: 1130-1139. 10.2337/dc05-2179.CrossRefPubMed
15.
go back to reference Meigs JB, Larson MG, D'Agostino R, Levy D, Clouse ME, Nathan DM, Wilson PWF, O'Donnell CJ: Coronary Artery Calcification in Type 2 Diabetes and Insulin Resistance. Diabetes Care. 2002, 25: 1313-1319. 10.2337/diacare.25.8.1313.CrossRefPubMed Meigs JB, Larson MG, D'Agostino R, Levy D, Clouse ME, Nathan DM, Wilson PWF, O'Donnell CJ: Coronary Artery Calcification in Type 2 Diabetes and Insulin Resistance. Diabetes Care. 2002, 25: 1313-1319. 10.2337/diacare.25.8.1313.CrossRefPubMed
16.
go back to reference Hunt KJ, Williams K, Rivera D, O'Leary DH, Haffner SM, Stern MP, Gonzales Villalpando C: Elevated carotid artery intima-media thickness levels in individuals who subsequently develop type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003, 23: 1845-1850. 10.1161/01.ATV.0000093471.58663.ED.CrossRefPubMed Hunt KJ, Williams K, Rivera D, O'Leary DH, Haffner SM, Stern MP, Gonzales Villalpando C: Elevated carotid artery intima-media thickness levels in individuals who subsequently develop type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003, 23: 1845-1850. 10.1161/01.ATV.0000093471.58663.ED.CrossRefPubMed
17.
go back to reference Lentzen M: Euro Heart Survey. Eur Heart J. 2006, 24: 2969-74. 10.1093/eurheartj/ehl363.CrossRef Lentzen M: Euro Heart Survey. Eur Heart J. 2006, 24: 2969-74. 10.1093/eurheartj/ehl363.CrossRef
18.
go back to reference Mohan V, Gokulakrishnan K, Sandeep S, Srivastava BK, Ravikumar R, Deepa R: Intimal media thickness, glucose intolerance and metabolic syndrome in Asian Indians--the Chennai Urban Rural Epidemiology Study (CURES-22). Diabet Med. 2006, 23: 845-50. 10.1111/j.1464-5491.2006.01898.x.CrossRefPubMed Mohan V, Gokulakrishnan K, Sandeep S, Srivastava BK, Ravikumar R, Deepa R: Intimal media thickness, glucose intolerance and metabolic syndrome in Asian Indians--the Chennai Urban Rural Epidemiology Study (CURES-22). Diabet Med. 2006, 23: 845-50. 10.1111/j.1464-5491.2006.01898.x.CrossRefPubMed
19.
go back to reference Isomaa B, Almgren P, Tuomi Y, Björn F, Lahti K, Nissén M, Taskinen M-R, Groop L: Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. Diabetes Care. 2001, 24: 683-689. 10.2337/diacare.24.4.683.CrossRefPubMed Isomaa B, Almgren P, Tuomi Y, Björn F, Lahti K, Nissén M, Taskinen M-R, Groop L: Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome. Diabetes Care. 2001, 24: 683-689. 10.2337/diacare.24.4.683.CrossRefPubMed
20.
go back to reference Kannel WB, Wilson PW, Zhang TJ: The epidemiology of impaired glucose tolerance and hypertension. Am Heart J April. 1991, 21: 1268-73. 10.1016/0002-8703(91)90432-H.CrossRef Kannel WB, Wilson PW, Zhang TJ: The epidemiology of impaired glucose tolerance and hypertension. Am Heart J April. 1991, 21: 1268-73. 10.1016/0002-8703(91)90432-H.CrossRef
21.
go back to reference Norhammar A, Bartnik M: Glucose Tolerance in Patients with Myocardial Infarction. Lancet. 2002, 359: 2140-4. 10.1016/S0140-6736(02)09089-X.CrossRefPubMed Norhammar A, Bartnik M: Glucose Tolerance in Patients with Myocardial Infarction. Lancet. 2002, 359: 2140-4. 10.1016/S0140-6736(02)09089-X.CrossRefPubMed
23.
go back to reference Gokulakrishnan K, Deepa R, Mohan V: Association of high sensitivity C-reactive protein (hsCRP) and tumour necrosis factor-alpha (TNF-alpha) with carotid intimal medial thickness in subjects with different grades of glucose intolerance--the Chennai Urban Rural Epidemiology Study (CURES-31). Clin Biochem. 2008, 41: 480-5.CrossRefPubMed Gokulakrishnan K, Deepa R, Mohan V: Association of high sensitivity C-reactive protein (hsCRP) and tumour necrosis factor-alpha (TNF-alpha) with carotid intimal medial thickness in subjects with different grades of glucose intolerance--the Chennai Urban Rural Epidemiology Study (CURES-31). Clin Biochem. 2008, 41: 480-5.CrossRefPubMed
24.
go back to reference Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa : Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999, 22: 920-924. 10.2337/diacare.22.6.920.CrossRefPubMed Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa : Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999, 22: 920-924. 10.2337/diacare.22.6.920.CrossRefPubMed
25.
go back to reference Saydah SH, Loria CM, Eberhardt MS, Brancati FL: Subclinical States of Glucose Intolerance and Risk of Death in the U.S. Diabetes Care. 2001, 24: 447-453. 10.2337/diacare.24.3.447.CrossRefPubMed Saydah SH, Loria CM, Eberhardt MS, Brancati FL: Subclinical States of Glucose Intolerance and Risk of Death in the U.S. Diabetes Care. 2001, 24: 447-453. 10.2337/diacare.24.3.447.CrossRefPubMed
26.
go back to reference American Diabetes Association: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1998, S5-Suppl 1 American Diabetes Association: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1998, S5-Suppl 1
27.
28.
go back to reference Nilsson PM, Engstrom G, Hedblad B: The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects--a population-based study comparing three different definitions. Diabetic Medicine. 2007, 24: 464-72. 10.1111/j.1464-5491.2007.02142.x.CrossRefPubMed Nilsson PM, Engstrom G, Hedblad B: The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects--a population-based study comparing three different definitions. Diabetic Medicine. 2007, 24: 464-72. 10.1111/j.1464-5491.2007.02142.x.CrossRefPubMed
29.
go back to reference Pan XR, Li GW, Hu YH, Wang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997, 20: 537-544. 10.2337/diacare.20.4.537.CrossRefPubMed Pan XR, Li GW, Hu YH, Wang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997, 20: 537-544. 10.2337/diacare.20.4.537.CrossRefPubMed
30.
go back to reference Tuomiehto J, Lindström J, Louheranta A, Valle TT, Hamalainen H, Rastas M, Ilanne-Parikka P, Saminen V, Eriksson J, Keinanen-Kiukaanniemi S, Laakso M, Uusitupa M: The Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impared glucose tolerance. N Engl J Med. 2001, 344: 1343-1350. 10.1056/NEJM200105033441801.CrossRef Tuomiehto J, Lindström J, Louheranta A, Valle TT, Hamalainen H, Rastas M, Ilanne-Parikka P, Saminen V, Eriksson J, Keinanen-Kiukaanniemi S, Laakso M, Uusitupa M: The Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impared glucose tolerance. N Engl J Med. 2001, 344: 1343-1350. 10.1056/NEJM200105033441801.CrossRef
31.
go back to reference Watanabe M, Yamaoka K, Yokotsuka M, Tango T: Randomized Controlled Trial of a New Dietary Education Program to Prevent Type 2 Diabetes in a Hight-Risk Group of Japonese Male Workers. Diabetes Care. 2003, 26: 3209-3214. 10.2337/diacare.26.12.3209.CrossRefPubMed Watanabe M, Yamaoka K, Yokotsuka M, Tango T: Randomized Controlled Trial of a New Dietary Education Program to Prevent Type 2 Diabetes in a Hight-Risk Group of Japonese Male Workers. Diabetes Care. 2003, 26: 3209-3214. 10.2337/diacare.26.12.3209.CrossRefPubMed
32.
go back to reference Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M: The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inihibiton to prevent type 2 diabetes in a population with impaired glucose tolerance. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care. 1998, 21: 1720-1725. 10.2337/diacare.21.10.1720.CrossRefPubMed Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M: The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inihibiton to prevent type 2 diabetes in a population with impaired glucose tolerance. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care. 1998, 21: 1720-1725. 10.2337/diacare.21.10.1720.CrossRefPubMed
33.
go back to reference Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE: and Prevention of Type 2 Diabetes with Troglitazone in the Diabetes Prevention Program: TRIPOD. Diabetes. 2005, 54: 1150-1156. 10.2337/diabetes.54.4.1150.CrossRefPubMed Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE: and Prevention of Type 2 Diabetes with Troglitazone in the Diabetes Prevention Program: TRIPOD. Diabetes. 2005, 54: 1150-1156. 10.2337/diabetes.54.4.1150.CrossRefPubMed
34.
go back to reference DREAM Trial Investigatores: Effect of Rosiglitazone on the frequency of diabetes in patients wiyh impaired glucose tolerance or impaired fasting glucose: randomised controlled trial. Lancet. 2006, 368: 1096-1105. 10.1016/S0140-6736(06)69420-8.CrossRef DREAM Trial Investigatores: Effect of Rosiglitazone on the frequency of diabetes in patients wiyh impaired glucose tolerance or impaired fasting glucose: randomised controlled trial. Lancet. 2006, 368: 1096-1105. 10.1016/S0140-6736(06)69420-8.CrossRef
35.
go back to reference Nathan DM: Medical management of hyperdysglicaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008, 31: 1-11. 10.2337/dc08-0545.CrossRef Nathan DM: Medical management of hyperdysglicaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008, 31: 1-11. 10.2337/dc08-0545.CrossRef
36.
go back to reference Barr ELM, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE: Continuous relationships between non-diabetic hyperdysglicaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009, 52: 415-424. 10.1007/s00125-008-1246-y.CrossRefPubMed Barr ELM, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE: Continuous relationships between non-diabetic hyperdysglicaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009, 52: 415-424. 10.1007/s00125-008-1246-y.CrossRefPubMed
37.
go back to reference Nichols GA, Hillier TA, Brown JB: Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. The American Journal of Medicine. 2008, 121: 519-524. 10.1016/j.amjmed.2008.02.026.CrossRefPubMed Nichols GA, Hillier TA, Brown JB: Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. The American Journal of Medicine. 2008, 121: 519-524. 10.1016/j.amjmed.2008.02.026.CrossRefPubMed
38.
go back to reference Malerbi D, Franco LJ: The Brazilian Cooperative Group on the study of Diabetes Prevalence. Multicenter study of the prevalence of diabetes mellitus and Impaired Glucose Tolerance in the urban Brasilian population aged 30-69 years. Diabetes Care. 1992, 15: 1509-1516. 10.2337/diacare.15.11.1509.CrossRefPubMed Malerbi D, Franco LJ: The Brazilian Cooperative Group on the study of Diabetes Prevalence. Multicenter study of the prevalence of diabetes mellitus and Impaired Glucose Tolerance in the urban Brasilian population aged 30-69 years. Diabetes Care. 1992, 15: 1509-1516. 10.2337/diacare.15.11.1509.CrossRefPubMed
39.
go back to reference Torquato MT, Montenegro Jnr RM, Viana LA, de Souza RA, Lanna CM, Lucas JC, Bidurin C, Foss MC: Prevalence of diabetes mellitus and impaired glucose tolerance in the urban population aged 30-69 years in Ribeirão Preto. Med J. 2003, 121 (6): 224-230. Torquato MT, Montenegro Jnr RM, Viana LA, de Souza RA, Lanna CM, Lucas JC, Bidurin C, Foss MC: Prevalence of diabetes mellitus and impaired glucose tolerance in the urban population aged 30-69 years in Ribeirão Preto. Med J. 2003, 121 (6): 224-230.
40.
go back to reference Gomes MB, Giannella D, Faria M, Tambascia M, Fonseca RM, Réa R, Macedo G, Modesto Filho J, Schmid H, Bittencourt AV, Cavalcanti S, Rassi N, Pedrosa H, Dib SA: Estimating the cardiovascular risk in patients with diabetes type 2: A National Multicenter Study in Brazil. Diabetol Metab Syndr. 2009, 1 (1): 22-10.1186/1758-5996-1-22.PubMedCentralCrossRefPubMed Gomes MB, Giannella D, Faria M, Tambascia M, Fonseca RM, Réa R, Macedo G, Modesto Filho J, Schmid H, Bittencourt AV, Cavalcanti S, Rassi N, Pedrosa H, Dib SA: Estimating the cardiovascular risk in patients with diabetes type 2: A National Multicenter Study in Brazil. Diabetol Metab Syndr. 2009, 1 (1): 22-10.1186/1758-5996-1-22.PubMedCentralCrossRefPubMed
Metadata
Title
Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist
Authors
Maria Eliane C Magalhães
Breno A Cavalcanti
Saulo Cavalcanti
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2010
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-2-2

Other articles of this Issue 1/2010

Diabetology & Metabolic Syndrome 1/2010 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.